BIIB074 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Inherited Erythromelalgia
Conditions
Primary Inherited Erythromelalgia
Trial Timeline
Sep 9, 2016 → Jan 5, 2017
NCT ID
NCT02917187About BIIB074 + Placebo
BIIB074 + Placebo is a phase 2 stage product being developed by Biogen for Primary Inherited Erythromelalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02917187. Target conditions include Primary Inherited Erythromelalgia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Inherited Erythromelalgia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03070132 | Phase 3 | Withdrawn |
| NCT03637387 | Phase 3 | Withdrawn |
| NCT03339336 | Phase 2 | Terminated |
| NCT02935608 | Phase 2 | Completed |
| NCT02917187 | Phase 2 | Completed |
| NCT02831517 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Inherited Erythromelalgia